Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on March 16, 2006. The report discloses the entry into a material definitive agreement regarding the company's principal executive offices located at 300 Third Street, Cambridge, Massachusetts.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific contractual agreement and does not contain financial statements or performance metrics.
Material Changes
On March 16, 2006, Alnylam entered into a First Amendment to Lease with ARE-MA Region No. 28, LLC. Key details include:
- Parties: Alnylam Pharmaceuticals, Inc. and the Landlord (successor to Three Hundred Third Street LLC).
- Subject: Amendment to the original Lease dated September 26, 2003, which was originally signed by a wholly-owned subsidiary, Alnylam U.S., Inc., and subsequently assigned to Alnylam.
- Purpose: The amendment relates to the lease of additional space at the existing premises in Cambridge, Massachusetts.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items beyond the disclosure of the lease amendment itself.
Investor Verification Checklist
- Verify the specific square footage and cost implications of the "additional space" mentioned in the First Amendment to Lease (Exhibit 10.1).
- Confirm the total lease term and expiration date following this amendment.
- Review the assignment of the original lease from the subsidiary (Alnylam U.S., Inc.) to the parent company to ensure all obligations were properly transferred.